Company Name | AbbVie Biopharmaceuticals GmbH |
---|---|
Protocol Number | P20-272 |
Title of Study | Prospective Observational Cohort study of patients with moderate to severe chronic plaque psoriasis in Taiwan |
Primary Objective | To characterize the short-term response of risankizumab compared to other biologics measured by the proportion of patients achieving PASI 90 response at week 24 in adult patients with moderate to severe chronic plaque psoriasis who are naïve or experienced to biological therapy. |
Number of Sites | 8 |
Period of Study | From:01-Jan-2021 to:31-Dec-2024 |
Number of Patients | 240人 |
IRB Approval Date | CGMFLK 28-Apr-2021 CMUH 11-Jan-2021 HLTCH 11-Feb-2021 KMUH 09-Mar-2021 NCKUH 24-Mar-2021 NTUH 26-Feb-2021 NTUH-HsinChu 05-Jul-2021 SHH 25-Feb-2021 |
Publication Plan / Date | Planned Year 2025 |